Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

AIMS: Co-primary objectives were to evaluate dalcetrapib (JTT-705/RO4607381), which targets cholesteryl ester transfer protein (CETP), effects on high-density lipoprotein cholesterol (HDL-C) in participants with coronary heart disease or risk equivalents and to evaluate potential changes in mesenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Evan A., Roth, Eli M., Rhyne, James M., Burgess, Tracy, Kallend, David, Robinson, Jennifer G.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821630/
https://www.ncbi.nlm.nih.gov/pubmed/20097702
http://dx.doi.org/10.1093/eurheartj/ehp601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821630/
https://www.ncbi.nlm.nih.gov/pubmed/20097702
http://dx.doi.org/10.1093/eurheartj/ehp601

Ejemplares similares